drugset / Trial / NCT03167307

The Omega-3 Fatty Acid Paediatric Depression Trial

NCT03167307

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study investigates the therapeutic efficacy and safety of omega-3 fatty acids rich in eicosapentaenoic acid / docosahexaenoic acid in pediatric depression in a nine months double-blind multi-centre study in 220 children and adolescents between 8 and 17 years of age. Inflammatory and bioactive lipid markers as predictors of response are evaluated. The relationship between omega-3 fatty acids with psychopathology, illness course and cognitive parameters will be further investigated.

Timeline

Start
2017-04-28
Primary completion
2022-03-24
Completion
2022-03-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovaza Other / unclassified 750 mg
Subject Lovaza Other / unclassified 1500 mg

Indications